Instil Bio News

Instil Bio Is Maintained at Outperform by Baird

Instil Bio Is Maintained at Outperform by Baird

Dow JonesMay 13 07:11

Baird: Maintaining the Instil Bio (TIL.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $54.00 to $32.00.

Baird: Maintaining the Instil Bio (TIL.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $54.00 to $32.00.

Zhitong FinanceMay 13 07:03

Baird Maintains Outperform on Instil Bio, Lowers Price Target to $32

Baird analyst Jack Allen maintains Instil Bio with a Outperform and lowers the price target from $54 to $32.

Analyst UpgradesMay 13 07:00

Instil Bio, Inc. Q1 Loss Decreases

RTTNewsMay 10 07:10

Instil Bio | 10-Q: Quarterly report

Futu NewsMay 10 06:14 · Announcements

Instil Bio Q1 2024 GAAP EPS $(2.39) Misses $(2.23) Estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) by 7.17 percent.

BenzingaMay 10 06:06

Instil Bio 1Q Research and Development Expenses $7.3M >TIL

Instil Bio 1Q Research and Development Expenses $7.3M >TIL

Dow JonesMay 10 06:01

Press Release: Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceu

Dow JonesMay 10 06:00

Instil Bio 1Q Loss/Shr $3.74 >TIL

Instil Bio 1Q Loss/Shr $3.74 >TIL

Dow JonesMay 10 06:00

Instil Bio Announces Board Reshuffle Following Resignation

TipRanksApr 26 15:14

Instil Bio Cut to Hold From Buy by Jefferies

Instil Bio Cut to Hold From Buy by Jefferies

Dow JonesApr 12 08:34

Jefferies Investment Bank: Downgraded the Instil Bio (TIL.US) rating from buy to hold, and adjusted the target price from $5.00 to $11.00.

Jefferies Investment Bank: Downgraded the Instil Bio (TIL.US) rating from buy to hold, and adjusted the target price from $5.00 to $11.00.

Zhitong FinanceApr 12 08:30

Jefferies Downgrades Instil Bio to Hold, Raises Price Target to $11

Jefferies analyst Kelly Shi downgrades Instil Bio (NASDAQ:TIL) from Buy to Hold and raises the price target from $5 to $11.

BenzingaApr 12 08:24

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)

TipRanksApr 12 04:20

HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $18 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.

BenzingaMar 25 05:08

Instil Bio Non-GAAP EPS of -$1.26 Beats by $2.14

Seeking AlphaMar 22 03:09

Instil Bio Q4 Adj EPS $(1.26) Beats $(2.85) Estimate

Instil Bio (NASDAQ:TIL) reported quarterly Adj losses of $(1.26) per share which beat the analyst consensus estimate of $(2.85) by 55.79 percent.

BenzingaMar 21 16:08

Instil Bio Sees Cash Runway Beyond 2026 >TIL

Instil Bio Sees Cash Runway Beyond 2026 >TIL

Dow JonesMar 21 16:04

Instil Bio 4Q Loss/Shr $1.99 >TIL

Instil Bio 4Q Loss/Shr $1.99 >TIL

Dow JonesMar 21 16:02

Press Release: Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-s

Dow JonesMar 21 16:00